Technology — GlycoNex, Inc.

Capabilities

Antibody Technologies

GlycoSH Anti-Glycan Antibody Library

GlycoSH is GlycoNex's proprietary collection of monoclonal antibodies that recognize disease-associated glycan structures. The library provides a foundation for identifying antibodies against glycan epitopes that may be difficult to address through conventional protein-targeted approaches.

Antibodies selected from GlycoSH can be further characterized and developed for therapeutic applications, including monoclonal antibodies, antibody-drug conjugates, and other antibody-based formats.

Antibody Development Platform

GlycoNex has established an integrated antibody development platform supporting programs from target and lead identification through preclinical and clinical-stage development.

The platform encompasses antibody generation and screening, lead selection and optimization, functional characterization, cell line development, process and formulation development, analytical development, scale-up, GMP-compliant manufacturing, and clinical development support. By integrating these capabilities within one organization, GlycoNex can maintain continuity of product knowledge and closely connect antibody design with manufacturability, quality, and biological function.

Pipeline Architecture

An End-to-End Pipeline

Discovery

GlycoSH antibody bank

Drug Format

ADC + Pro-Antibody

Manufacturing

200L GMP facility

Capabilities

Glycan Technologies

Glycans are structurally diverse biomolecules that require specialized methods for their isolation, preparation, and characterization. GlycoNex has developed a suite of glycan technologies to support glycan research, antibody discovery, product characterization, and biopharmaceutical development.

Glycan Isolation and Purification

Isolation and purification of glycans from biological materials to obtain defined glycan fractions or structures for subsequent characterization, antibody screening, and research applications.

Glycan Semi-Synthesis

Preparation and structural modification of glycans using naturally derived carbohydrate materials as starting points. This capability supports access to glycan structures and derivatives for analytical, biological, and antibody-development applications.

Glycan Structure Analysis

Structural characterization of glycans to determine their composition, branching patterns, linkages, and other structural features relevant to biological activity and product quality.

Glycosylation-Site Analysis

Identification and characterization of glycosylation sites on proteins, providing insight into the location and distribution of protein-associated glycans and their potential effects on molecular structure and function.

Monosaccharide Analysis

Qualitative and quantitative analysis of the monosaccharide components of glycans and glycoproteins, supporting structural characterization, compositional assessment, and product comparability.

Integration

Connecting Glycan Science with Antibody Development

By bringing glycan preparation and analysis together with antibody discovery and development, GlycoNex can investigate disease-associated glycan structures, generate antibodies that recognize them, and translate selected candidates into developable therapeutic programs. This integrated approach forms the technological foundation of GlycoNex's glycan-targeted antibody and ADC pipeline.

GlycoSH Antibody Bank The anti-glycan antibody collection in detail, and the glycosylation analytics platform behind it. Glycan-Directed ADCs How anti-glycan antibodies become antibody-drug conjugates, and why the glycan target matters. Pro-Antibody Format Antibody lock technology, in-licensed from Precisemab, that activates in the tumor microenvironment. Patent Portfolio 36 granted patents across multiple jurisdictions — titles and numbers listed for due diligence.

Validation

Scientific and Regulatory Validation

Peer-Reviewed Science

Glycobiology and oncology publications spanning more than two decades, including foundational work in collaboration with the late Dr. Sen-itiroh Hakomori and ongoing translational research with Hokkaido University Hospital.

View publications →

Conference Presentations

Recent presentations include AACR 2025 (preclinical data on GNX1021), the J.P. Morgan Healthcare Conference Biotech Showcase 2025, and ongoing engagement with international oncology and biosimilar communities.

View presentations →

Regulatory Milestones

GNX1021 advances into first-in-human Phase 1 — Q3 2026.
SPD8 Phase 3 top-line data — Q2 2026.

View pipeline →

Patent Portfolio

36 granted patents across multiple jurisdictions, spanning the GNX1021 / GNX102 antibody family and the licensed GNX8 program, with further applications published and pending. These filings cover glycan-directed antibody compositions and their therapeutic applications, built on two decades of glycobiology.

View patent portfolio →

An Integrated Platform for Glycan-Directed Oncology